NASDAQ:ORPH Orphazyme A/S (ORPH) Stock Price, News & Analysis → What’s Really Next for America… (From Porter & Company) (Ad) Free ORPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.57▼$2.2152-Week Range N/AVolume941,400 shsAverage Volume1.37 million shsMarket Capitalization$30.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Orphazyme A/S alerts: Email Address Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Orphazyme A/S Stock (NASDAQ:ORPH)Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.Read More Ad Crypto 101 MediaShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. ORPH Stock News HeadlinesMay 7, 2024 | foxnews.comSome Alzheimer's cases may be caused by copies of a single gene, research showsMay 7, 2024 | nytimes.comStudy Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’sMay 7, 2024 | abcnews.go.comA gene long thought to just raise the risk for Alzheimer's may cause some casesMay 6, 2024 | msn.comGenes known to increase the risk of Alzheimer’s may actually be an inherited form of the disorder, researchers sayMay 6, 2024 | msn.comScientists may have found a way to make a universal donor bloodMay 3, 2024 | yahoo.comAllozymes puts its accelerated enzymatics to work on a data and AI play, raising $15MMay 2, 2024 | msn.comRapamycin shows promise in slowing Alzheimer's disease progression linked to seizuresMay 1, 2024 | msn.comOrgan transplant drug may slow Alzheimer's disease progressionApril 30, 2024 | msn.comStrategic Innovation in SARMs: OTR-AC's Esterification AdvantageApril 27, 2024 | msn.comOrpheus Pledger was on SAS Australia for a 'redemption arc'. Now there's been a manhunt for him.April 20, 2024 | msn.comPhase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patientsApril 19, 2024 | msn.comOlympic torch makes Acropolis overnight stop a week before handover to Paris organizersApril 18, 2024 | nbcnews.comInside Gen Alpha’s controversial obsession with skincareApril 13, 2024 | msn.comIt’s the first drug shown to slow Alzheimer’s. Why is is it off to a slow start?April 12, 2024 | msn.comLysine Is Important for the Body, and Is Generally a Safe SupplementApril 11, 2024 | markets.businessinsider.comZevra Therapeutics: Strong Buy on Strategic Financing and Promising Drug PortfolioApril 8, 2024 | msn.comFrom fungi to feast: The rise of Mycoprotein as a sustainable protein solutionApril 3, 2024 | msn.comAsk A Doctor: What Diseases Cause Encephalopathy?April 1, 2024 | msn.comChemists discover a key protein in how lysosomes workMarch 28, 2024 | msn.comOrry refuses to shake woman’s hand citing ‘germs,’ threatens legal action after her videoMarch 28, 2024 | msn.comA Guide To Pokémon's Poison TypeMarch 18, 2024 | msn.comUnderstanding what causes trastuzumab's cardiotoxicityMarch 16, 2024 | msn.comHow a brash, red-haired orphan from P.E.I. continues to be a worldwide sensationMarch 14, 2024 | msn.comSindica - A Novel, Patented Post-emergence Herbicide for Sugarcane from AtulMarch 12, 2024 | msn.comSharing a Drink With Orphaned Opossum BabiesSee More Headlines Receive ORPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orphazyme A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPH CUSIPN/A CIK1764791 Webwww.orphazyme.com Phone45-2898-9055FaxN/AEmployees141Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.14 Current Ratio1.80 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.74 per share Price / BookN/AMiscellaneous Outstanding Shares35,312,000Free FloatN/AMarket Cap$30.72 million OptionableNot Optionable Beta1.68 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Anders Fink Vadsholt M.B.A. (Age 52)M.Sc., MBA, Chief Financial Officer Comp: $924.24kMr. Christophe Bourdon M.B.A. (Age 51)Chief Exec. Officer Dr. Thomas Kirkegaard Jensen Ph.D. (Age 44)Co-Founder & Chief Scientific Officer Ms. Molly Carey PoarchHead of Global CommunicationsDr. Thomas Blaettler (Age 54)Chief Medical Officer Ms. Molly Painter (Age 45)Pres of Orphazyme US, Inc. More ExecutivesKey CompetitorsTheratechnologiesNASDAQ:THTXViracta TherapeuticsNASDAQ:VIRXImmunoPrecise AntibodiesNASDAQ:IPADaré BioscienceNASDAQ:DAREApollomicsNASDAQ:APLMView All Competitors ORPH Stock Analysis - Frequently Asked Questions When did Orphazyme A/S IPO? Orphazyme A/S (ORPH) raised $100 million in an IPO on Tuesday, September 29th 2020. The company issued 7,600,000 shares at a price of $13.13 per share. BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO and Danske Markets was co-manager. This page (NASDAQ:ORPH) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaProtect Your Bank Account Before It’s Too LateWeiss RatingsHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orphazyme A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.